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The transcription factor CREB is involved in sorafenib-inhibited 
renal cancer cell proliferation, migration and invasion
Our previous reports showed that the cyclic-AMP-response 
element-binding protein (CREB) served as a proto-onco-
gene in the process of tumorigenesis and mediated the 
growth and metastatic activity of renal cancer cells. Our 
study, therefore, explored the role of CREB in sorafenib- 
-inhibited cell proliferation, migration and invasion. Renal 
cancer cells were cultured in medium containing sorafenib 
for 12, 24, 48 and 72 h. The MTT assay was used to study the 
cytotoxic effects of sorafenib. Cell invasion and migration 
were assayed in wound healing and transwell experiments, 
respectively. Protein expression levels were evaluated by 
western blotting. The results show that sorafenib treatment 
decreased cell viability in a dose- and time-dependent 
manner. Sorafenib inhibited cell migration and invasion 
and decreased the expression of MMP-2 and MMP-9. 
Moreover, addition of the recombinant plasmid pCI-neo/
CREB (PN) reversed the sorafenib-induced inhibition of 
cell proliferation, migration and invasion. These results 
show that CREB is associated with the sorafenib-induced 
inhibition of proliferation, migration and invasion.
Keywords: CREB, renal cancer, sorafenib, migration, invasion
Renal cell carcinoma (RCC) is the most frequent malignancy of the kidney. RCC is a 
highly vascularized cancer associated with metabolic diseases. Due to frequent metastases, 
only 1/3 of RCCs can be effectively managed by resection, chemotherapy and radiotherapy 
(1–3). Unlike previous therapies, anti-angiogenic targeted therapies are effective for the ad-
vanced or late stage RCC. Among these, sorafenib is a novel molecular inhibitor of multi-
tyrosine kinases (PDGFR and VEGFR) and the RAF/MEK/ERK cascade pathway (4, 5). This 
effect causes inhibition of growth signaling and angiogenesis (6–8). Unfortunately, in previ-
ous clinical uses, sorafenib functioned with variable efficacy for individuals (9, 10). More 
efforts need to be focused on the changes in proto-oncogenes after sorafenib treatment.
The cyclic-AMP-response element-binding (CREB) protein, a proto-oncogenic tran-
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to diverse extracellular signals, kinases such as MAPK and PKA are involved in the phos-
phorylation of CREB at the Ser-133 residue, thus increasing expression levels of its target 
genes (13). Increasing evidence has demonstrated that CREB phosphorylation is necessary 
for cell survival and for promoting tumorigenesis (14–16). Our previous reports showed 
that a CRE decoy could block the CREB binding site of its targeted genes (cyclins and bcl-2), 
thus abrogating the anti-tumor drug-induced cell apoptosis and cell cycle arrest (3, 17–18). 
Nonetheless, the possible role of pCREB in the progression of sorafenib-treated RCC 
growth and metastasis has not been investigated. In this study, we used the recombinant 
plasmid pCI-neo/CREB (PN) (constitutively active CREB at Ser-133) (19) to investigate the 
role of CREB in sorafenib-treated RCC cell lines and demonstrate its effects on cell proli-
feration and migration under CREB signaling.
EXPERIMENTAL
Cell culture and treatment
We obtained the human renal carcinoma cell lines ACHN, 786-O and OS-RC-2 from 
the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). 786-O and OS-RC-2 
cells were cultured in RPMI 1640 medium, and ACHN cells were cultured in DMEM (Hy-
Clone, UT, USA). Both media were supplemented with 10 % heat inactivated fetal bovine 
serum (HyClone, Auckland, NZ), 100 U mL–1 streptomycin and 100 mg mL–1 penicillin 
(HyClone, Auckland, NZ). The cultures were incubated at 37 °C in 5 % CO2.
Cells were treated with 0.50 μmol L–1 sorafenib (Bayer Healthcare, Leverkusen, Ger-
many) for 24 h for transwell and wound healing experiments. PN was transfected using 
the Lipofectamine 2000 transfection reagent (Invitrogen, USA) following the manufac-
turer’s instructions.
Cell proliferation assay
Cell proliferation was calculated using the CellTiter96® Aqueous One Solution Cell 
Proliferation Assay (Promega, USA). In short, 2000 cells were plated in each well of a 96-
well plate and received treatment with sorafenib at different concentrations (0.05, 0.10, 0.20, 
0.50, 1.0 and 2.0 μmol L–1) or different times (12, 24, 48 and 72 h). Four hours before the end 
of the study, 20 μL of CellTiter 96® Aqueous One Solution Reagent was added to each well. 
The absorbance at 492 nm was measured using a spectrophotometer.
Western blotting
Cells were lysed with RIPA buffer (Solarbio, Beijing, China) containing the 1 % prote-
ase inhibitor PMSF (Solarbio, Beijing, China). Total protein concentrations were measured 
using a BCA protein assay kit (Beyotime, Beijing, China). For western blot analysis, each 
sample (35 μg) was loaded and separated using 12 % SDS-PAGE, transferred onto PVDF 
membranes, blocked with 5 % non-fat dry milk (diluted with TBST), incubated with spe-
cific primary antibodies overnight at 4 °C as follows: rabbit monoclonal anti-CREB (Cell 
Signaling, Boston, catalog no. 9197, 1:1000), rabbit monoclonal anti-CREB (Ser-133) (Cell 
Signaling, Boston, catalog no. 9198, 1:1000), rabbit monoclonal anti-MMP-2 (Abcam, Cam-
bridge, catalog no. 7033, 1:1000), rabbit monoclonal anti-MMP-9 (Abcam, Cambridge, cata-
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log no. 137651, 1:1000) and rabbit monoclonal GAPDH (Cell Signaling, Boston, catalog no. 
5174, 1:2000). After washing with TBST, the blots were incubated with horseradish peroxi-
dase-labelled secondary antibody (Boster, Wuhan, catalog no. 1054, 1:5000) and visualized 
using an enhanced chemiluminescence reagent.
Wound healing assay
After the cells had grown to 70 % confluence, we made linear scratches with a micro-
pipette tip in the middle of the 24-well plate, washed the dislodged cells with PBS and re-
placed the culture medium with fresh serum-free medium. After 24 h, we quantified cell 
migration by measuring the wound width.
Transwell assay
The cell invasion assay was carried out in transwell inserts fitted with polycarbonate 
filters (8 μm pore size, Corning, NY, USA). Upper sides of filters were pre-coated with 
Matrigel (BD Biosciences, NJ, USA). Two days after transfection, the cells were plated at a 
density of 5.0 × 104 cells per upper well in 100 μL of culture medium (10 % FBS) and the 
lower chamber was filled with 500 μL of medium (20 % medium). Cells were allowed to 
invade for 24 h at 37 °C in 5 % CO2, following which, the non-invading cells in the upper 
surface of the membrane were removed by scrubbing with a cotton-tipped swab. Bottom 
cells were fixed in 4 % polyoxymethylene for 30 min and stained with 0.1 % crystal violet. 
The mean number of invading cells was counted under five preselected microscopic fields.
Statistical analysis
All experiments were repeated in triplicate. Data were expressed as means ± standard 
deviation using SPSS, version 18.0 (SPSS, Inc., Chicago, IL, USA). p < 0.05 was considered 
statistically significant for ANOVA and STD t-test.
RESULTS AND DISCUSSION
Clinical development of the targeted protein kinase inhibitor, sorafenib, offers hope for 
future treatment of patients with advanced RCC whose prognoses are poor. Studies have 
shown that sorafenib disrupted microvasculature and inhibited tumor proliferation through 
anti-angiogenic, anti-proliferative and/or pro-apoptotic effects (20–22). Its widely accepted 
preclinical and clinical activity occurs because of its multiple molecular targets (receptor 
tyrosine kinases and serine/threonine kinase Raf) (4–5). In this study, we investigated the 
cytotoxic effect of sorafenib on RCC cells (ACHN, 786-O and OS-RC-2) using the MTT assay. 
As shown in Fig. 1, sorafenib inhibited RCC cell growth in a time- and dose-dependent man-
ner. The IC50 values for sorafenib after 12, 24, 48 and 72 hours of treatment were calculated 
for each cell line (Table I). ACHN displayed relatively low cytotoxicity towards 786-O and 
OS-RC-2 cells. We, therefore, decided to further research 786-O and OS-RC-2 cells. To explore 
the effect of sorafenib on 786-O and OS-RC-2 cell migration and invasion, we treated cells 
with 0.50 μmol L–1 sorafenib in wound-healing and transwell experiments. In comparison 
with the control group, the sorafenib-treated group displayed significantly reduced migra-
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Fig. 1. Effect of sorafenib on ACHN, 786-O and OS-RC-2 cell proliferation. Cell viability was measured 
using the MTT assay. Data are presented as means ± SD of three independent experiments.
Fig. 2. Sorafenib inhibited 786-O and OS-RC-2 cell migration and invasion. Sorafenib decreased the 
migration (a) and invasion (b) capacities of 786-O cells. Representative graphs were derived from data 
obtained 24 h after treatment with 0.5 μmol L–1 sorafenib. Sorafenib significantly reduced the 
expression levels of MMP-2 and MMP-9 proteins compared to that in the controls (c). Data are 
presented as mean ± SD from three independent experiments. *p < 0.05, **p < 0.01 vs. the control group.
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tion distances and fewer invading cells, as well as downregulation of the MMP-2 and MMP-
9 expression levels (Fig. 2). These results indicated that sorafenib could inhibit the prolifera-
tion, migration and invasion of RCC cells, thereby substantiating its tumor-suppressive role 
in tumorigenesis.
It, however, remains unknown which of the downstream nuclear effectors participate 
in this process. Emerging evidence showed that CREB acted as a proto-oncogene in regula-
tion of numerous physiological processes, including tumor growth and metastasis (11, 23–
24). It is not clear whether CREB is involved in the sorafenib-induced inhibition of cell 
growth and metastasis. We, therefore, investigated CREB and pCREB modifications in 
sorafenib-treated 786-O and OS-RC-2 cells. Western blot analysis was used to observe pro-
tein changes in cells treated with 0, 0.05, 0.10, 0.20, 0.50 and 1.0 μmol L–1 sorafenib for 24 h. 
Interestingly, the results showed that sorafenib incubation inhibited pCREB levels in a con-
centration-dependent manner, with no obvious changes in total CREB expression (Fig. 3). 
Table I. The concentration producing 50 % growth inhibition (IC50) of sorafenib on renal cancer cells
Cell line
IC50 (μmol L–1)
12 h 24 h 48 h 72 h
ACHN 9.238 6.421 4.318 1.601
786-O 1.727 0.885 0.185 0.059
OS-RC-2 3.057 1.898 0.463 0.138
Fig. 3. Effect of sorafenib on pCREB and CREB expression. 786-O and OS-RC-2 cells were treated with 
0, 0.05, 0.10, 0.20, 0.50 and 1.0 μmol L–1 sorafenib for 24 h, and pCREB and CREB were assayed by 
western blotting. Results are represented as means ± SD from three independent experiments. *p < 
0.05, **p < 0.05, ***p < 0.001 vs. the control group.
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These data suggested that sorafenib was capable of reducing the activation of CREB in RCC 
cells.
To further confirm the role of CREB in sorafenib-regulated cell proliferation, we 
transfected cells with the CREB recombinant plasmid PN to enhance the pCREB levels 
within 786-O and OS-RC-2 cancer cells (Fig. 4a and b). MTT analysis showed that PN 
markedly increased the proliferation at 24 h, while co-treatment of sorafenib and PN 
reversed the sorafenib-inhibited cell proliferation (Fig. 4c and d). These results indicated 
that CREB signaling was involved in sorafenib-inhibited cell proliferation.
Furthermore, in the process of RCC tumorigenesis, two pivotal features of metastatic 
malignancies, migration and invasion, are thought to provide the metastatic potential of 
cancer cells (25). During this process, the extracellular matrix and components of the 
basement membrane are degraded by the concerted action of MMPs, allowing tumor cells 
to escape from the primary site more easily (26–27). Proteins such as MMP-2, MMP-9 
degrade laminin, gelatin and collagen, eventually disrupting the extracellular matrix 
structure and contributing to EMT progression and facilitating metastasis (28–29). In 
previous studies, we explored the changes of EMT-related proteins (E-cadherin, vimentin, 
N-cadherin, fibronectin) and MMP-2/9 when CREB was diminished. The results showed 
that reduction of pCREB could suppress RCC cell migration and regulate the expressions 
Fig. 4. Sorafenib regulated cell proliferation through CREB signaling. After 786-O and OS-RC-2 cells 
were treated with PN for 24 h, the expressions of pCREB and CREB were assayed by western blotting 
(a, b), and the cell viability was assayed by MTT (c, d). Data are presented as means ± SD, all experiment 
were repeated three times. *p < 0.05, **p < 0.01 vs. the control group.
a)                                                                            b)
c)                                                                            d)
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Fig. 5. Sorafenib regulated cell migration and invasion through CREB signaling. Migration and inva-
sion experiments were performed in 786-O and OS-RC-2 cells after treatment with PN for 24 h. Cell 
migration distances were evaluated by a wound healing assay (a, b), cell invasion was measured by 
the transwell assay (c, d) and the expression levels of MMP-2 and MMP-9 were assayed by western 
blotting (f, g). Data are presented as means ± SD, all experiment were repeated three times. *p < 0.05, 
**p < 0.01 vs. the control group.




e)                                                                       f)
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of N-cadherin, fibronectin, E-cadherin and MMP-2/9, but cannot affect the expression and 
distribution of vimentin because of the lack of CER sequence in the promoter of vimentin 
(24). Pradines et al. showed that CREB could regulate the transcriptional expression of 
MMP-9 and its inhibitor TIMP-1 (30). Park et al. revealed that CREB functioned in the 
signaling between Akt and MMP-2/MMP-9 and mediated the ICAM-3-induced cell 
migration and invasion in human non-small cell lung cancer cells (31). Similar results were 
also shown in human cholangiocarcinoma cells and human osteosarcomas (32–33). It, 
therefore, seemed that CREB signaling functioned as a regulator in the process of cell 
locomotion. To explore whether CREB played pivotal roles in the sorafenib-treated RCC 
cell migration and invasion, we treated cells with sorafenib, PN and their combinations. 
As expected, PN markedly boosted 786-O and OS-RC-2 cell migration distances. In 
comparison with sorafenib-treated cells, cells treated with the combination of PN and 
sorafenib had greater increases in their migration distances (Fig. 5a and b). Similarly, the 
sorafenib-reduced cell invasion was abrogated by addition of PN and sorafenib (Fig. 5c and 
d). In addition, we found that MMP-2 and MMP-9 expression levels were increased when 
pCREB was induced by PN. Compared to the sorafenib group, higher increases of MMP-2/
MMP-9 levels were observed with the combination of PN and sorafenib (Fig. 5e, f), 
indicating that CREB was an upstream regulator of MMP-2/MMP-9. These data verified 
the role of CREB-induced MMP-2/9 expression in the progression of tumor metastasis.
CONCLUSIONS
This study has demonstrated that CREB signaling is involved in the sorafenib-inhib-
ited cell proliferation, migration and invasion, accompanied by up-regulation of MMP-2 
and MMP-9. A search for more exact mechanisms will be conducted in our future study.
Acknowledgements. – We gratefully acknowledge Professor Michael Hehir of the Hong Lan Xin 
Consultancy and Samuel Selorm Fiati Kenston for revising the language. This work was supported 
by the Natural Science Foundation of Ningbo City (2016A610019) and the Science and Technology 
Project of Yinzhou District.
REFERENCES
 1.  C. W. Cheung, D.A. Vesey, D. L. Nicol and D. W. Johnson, The roles of IGF-I and IGFBP-3 in the 
regulation of proximal tubule, and renal cell carcinoma cell proliferation, Kidney Int. 65 (2004) 
1272–1279; https://doi.org/10.1111/j.1523-1755.2004.00535.x
 2.  M. Sun, G. Lughezzani, P. Perrotte and P. I. Karakiewicz, Treatment of metastatic renal cell carci-
noma, Nat. Rev. Urol. 7 (2010) 327–338; https://doi.org/10.1038/nrurol.2010.57
 3.  X. Wang, Y. Ren, H. Zhuang, X. Meng, S. Huang, Y. Li, M. Hehir and P. Wang, Decrease of phos-
phorylated proto-oncogene CREB at Ser 133 site inhibits growth and metastatic activity of renal 
cell cancer, Expert Opin. Ther. Targets 19 (2015) 985–995; https://doi.org/10.1517/14728222.2015.10532
08
 4.  L. Adnane, P. A. Trail, I. Taylor and S. M. Wilhelm, Sorafenib (BAY 43-9006, Nexavar), a dual-ac-
tion inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/
PDGFR in tumor vasculature, Methods Enzymol. 407 (2006) 597–612; https://doi.org/10.1016/S0076-
6879(05)07047-3
505
S. Huang et al.: The transcription factor CREB is involved in sorafenib-inhibited renal cancer cell proliferation, migration and invasion, 
Acta Pharm. 68 (2018) 497–506.
 
 5.  S. J. Oh, H. H. Erb, A. Hobisch, F. R. Santer and Z. Culig, Sorafenib decreases proliferation and 
induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signal-
ing pathways, Endocr. Relat. Cancer 19 (2012) 305–319; https://doi.org/10.1530/ERC-11-0298
 6.  T. Funakoshi, C. H. Lee and J. J. Hsieh, A systematic review of predictive and prognostic biomark-
ers for VEGF-targeted therapy in renal cell carcinoma, Cancer Treat. Rev. 40 (2014) 533–547; https://
doi.org/10.1016/j.ctrv.2013.11.008
 7.  K. Hui, Y. Yang, K. Shi, H. Luo, J. Duan, J. An, P, Wu, Y. Ci, L. Shi and C. Xu, The p38 MAPK-reg-
ulated PKD1/CREB/Bcl-2 pathway contributes to selenite-induced colorectal cancer cell apoptosis 
in vitro and in vivo, Cancer Lett. 354 (2014) 189–199; https://doi.org/10.1016/j.canlet.2014.08.009
 8.  M. Chuma, K. Terashita and N. Sakamoto, New molecularly targeted therapies against advanced 
hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions, 
Hepatol. Res. 45 (2015) 1–11; https://doi.org/10.1111/hepr.12459
 9.  H. Akaza, T. Tsukamoto, M. Murai, K. Nakajima and S. Naito, Phase II study to investigate the 
efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell 
carcinoma, Jpn. J. Clin. Oncol. 37 (2007) 755–762; https://doi.org/10.1093/jjco/hym095
10.  I .Tamaskar, J. A. Garcia, P. Elson, L. Wood, T. Mekhail, R. Dreicer, B. I. Rini and R. M. Bukowski, 
Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who 
received prior antiangiogenic therapy, J. Urol. 179 (2008) 81–86; https://doi.org/10.1016/j.
juro.2007.08.127
11.  X. Xiao, B. X. Li, B. Mitton, A. Ikeda and K. M. Sakamoto, Targeting CREB for cancer therapy: 
friend or foe, Curr. Cancer Drug Targets 10 (2010) 384–391; http://dx.doi.org/10.2174/156800910791208535
12.  C. M. Westbom, A  Shukla, M. B. MacPherson, E. C. Yasewicz, J. M. Miller, S. L. Beuschel, C. Steele, 
H. I. Pass, P. M. Vacek and A. Shukla, CREB-induced inflammation is important for malignant 
mesothelioma growth, Am. J. Pathol. 184 (2014) 2816–2827; https://doi.org/10.1016/j.ajpath.2014.06.008
13.  A. J. Shaywitz and M. E. Greenberg, CREB: a stimulus-induced transcription factor activated by a 
diverse array of extracellular signals, Annu. Rev. Biochem. 68 (1999) 821–861; https://doi.org/10.1146/
annurev.biochem.68.1.821
14.  Y. W. Wang, X. Chen, J. W. Gao, H. Zhang, R. R. Ma, Z. H. Gao and P. Gao, High expression of 
cAMP-responsive element-binding protein 1 (CREB1) is associated with metastasis, tumor stage 
and poor outcome in gastric cancer, Oncotarget 6 (2015) 10646–10657; https://doi.org/10.18632/onco-
target.3392
15.  S. S. Kentaro Kinjo, Kathleen M. Sakamoto, Deepa B. Shankar, The role of CREB as a proto-onco-
gene in hematopoiesis, Cell Cycle 4 (2005) 1134–1135;  http://dx.doi.org/10.4161/cc.4.9.1991
16.  M. Rao, Y. Zhu, X. Cong and Q. Li, Knockdown of CREB1 inhibits tumor growth of human gastric 
cancer in vitro and in vivo, Oncol. Rep. 37 (2017) 3361–3368; https://doi.org/10.3892/or.2017.5636
17.  P. Wang, J. Xu and C. Zhang, CREB, a possible upstream regulator of Bcl-2 in trichosanthin-in-
duced HeLa cell apoptosis, Mol. Biol. Rep. 37 (2010) 1891–1896; https://doi.org/10.1007/s11033-009-
9629-9
18.  P. Wang, S. Huang, F. Wang, Y. Ren, M. Hehir, X. Wang and J. Cai, Cyclic AMP-response element 
regulated cell cycle arrests in cancer cells, PLoS One 8 (2013) e65661; https://doi.org/10.1371/journal.
pone.0065661
19.  S. Huang, Y. Ren, P. Wang, Y. Li, X. Wang, H. Zhuang, R. Fang, Y. Wang, N. Liu, M. Hehir and J. 
X. Zhou, Transcription factor CREB is involved in CaSR-mediated cytoskeleton gene expression, 
Anat. Rec. (Hoboken) 298 (2015) 501–512; https://doi.org/10.1002/ar.23089
20.  N. Ibrahim, Y. Yu, W. R. Walsh and J. L. Yang, Molecular targeted therapies for cancer: sorafenib 
mono-therapy and its combination with other therapies (review), Oncol. Rep. 27 (2012) 1303–1311; 
https://doi.org/10.3892/or.2012.1675
506
S. Huang et al.: The transcription factor CREB is involved in sorafenib-inhibited renal cancer cell proliferation, migration and invasion, 
Acta Pharm. 68 (2018) 497–506.
 
21.  M. Madany, T. M. Thomas, L. Edwards and J. S. Yu, Immunobiology and immunotherapeutic 
targeting of glioma stem cells, Adv. Exp. Med. Biol. 853 (2015) 139–166; https://doi.org/10.1007/978-
3-319-16537-0_8
22.  L. Yadav, N. Puri, V. Rastogi, P. Satpute and V. Sharma, Tumour angiogenesis and angiogenic 
inhibitors: a review, J. Clin. Diagn. Res. 9 (2015) XE01-XE05; https://doi.org/10.7860/JCDR/2015/12016.6135
23.  E. C. Cho, B. Mitton and K. M. Sakamoto, CREB and leukemogenesis, Crit. Rev. Oncog. 16 (2011) 
37–46; http://dx.doi.org/10.1615/CritRevOncog.v16.i1-2.50
24.  X. Wang, H. Cui, Z. Lou, S. Huang, Y. Ren, P. Wang and G. Weng, Cyclic AMP responsive element-
binding protein induces metastatic renal cell carcinoma by mediating the expression of matrix 
metallopeptidase-2/9 and proteins associated with epithelial-mesenchymal transition, Mol. Med. 
Rep. 15 (2017) 4191–4198; https://doi.org/10.3892/mmr.2017.6519
25.  J. Ma, B. Fang, F. Zeng, C. Ma, H. Pang, L. Cheng, Y. Shi, H. Wang, B. Yin, J. Xia and Z. Wang, 
Down-regulation of miR-223 reverses epithelial-mesenchymal transition in gemcitabine-resistant 
pancreatic cancer cells, Oncotarget 6 (2015) 1740–1749; https://doi.org/10.18632/oncotarget.2714
26.  S. O. Yoon, S. J. Park, C. H. Yun and A. S. Chung, Roles of matrix metalloproteinases in tumor 
metastasis and angiogenesis, J. Biochem. Mol. Biol. 36 (2003) 128–137; https://doi.org/10.5483/BM-
BRep.2003.36.1.128
27.  A. Winer, S. Adams and P. Mignatti, Matrix metalloproteinase inhibitors in cancer therapy: Turn-
ing past failures into future successes, Mol. Cancer Ther. 5 (2018) 1–9; https://doi.org/10.1158/1535-
7163.MCT-17-0646
28.  S. Ghosh, M. Basu and S. S. Roy, ETS-1 protein regulates vascular endothelial growth factor-in-
duced matrix metalloproteinase-9 and matrix metalloproteinase-13 expression in human ovarian 
carcinoma cell line SKOV-3, J. Biol. Chem. 287 (2012) 15001–15015; https://doi.org/10.1074/jbc.
M111.284034
29.  T. Ren, L. Zhu and M. Cheng, CXCL10 accelerates EMT and metastasis by MMP-2 in hepatocel-
lular carcinoma, Am. J. Transl. Res. 9 (2017) 2824–2837; https://www.ncbi.nlm.nih.gov/pmc/articles/
PMC5489884/pdf/ajtr0009-2824.pdf
30.  E. Pradines, D. Loubet, B. Schneider, J. M. Launay, O. Kellermann and S. Mouillet-Richard, CREB-
dependent gene regulation by prion protein: impact on MMP-9 and beta-dystroglycan, Cell Signal. 
20 (2008) 2050–2058; https://doi.org/10.1016/j.cellsig.2008.07.016
31.  J. K. Park, S. H. Park, K. So, I. H. Bae, Y. D. Yoo and H. D. Um, ICAM-3 enhances the migratory and 
invasive potential of human non-small cell lung cancer cells by inducing MMP-2 and MMP-9 via 
Akt and CREB, Int. J. Oncol. 36 (2010) 181–192; https://doi.org/10.3892/ijo_00000489
32.  B. Sun, R. Rong, H. Jiang, H. Zhang, Y. Wang, X. Bai, M. Zhang, J. Ma, S. Xia, W. Shu, L. Zhang and 
J. Leng, Prostaglandin E2 receptor EP1 phosphorylate CREB and mediates MMP2 expression in 
human cholangiocarcinoma cells, Mol. Cell. Biochem. 378 (2013) 195–203; https://doi.org/10.1007/
s11010-013-1610-1
33.  S. F. Yang, W. J. Lee, P. Tan, C. H. Tang, M. Hsiao, F. K. Hsieh and M. H. Chien, Upregulation of 
miR-328 and inhibition of CREB-DNA-binding activity are critical for resveratrol-mediated sup-
pression of matrix metalloproteinase-2 and subsequent metastatic ability in human osteosarco-
mas, Oncotarget 6 (2015) 2736–2753; https://doi.org/10.18632/oncotarget.3088
